HA
BCYC

HHLR Advisors’s Bicycle Therapeutics BCYC Stock Holding History

HHLR Advisors’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-125,283
Closed -$2.54M – 57
2024
Q2 		$2.54M Buy
+125,283
New +$2.83M 0.06% 50

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

HHLR Advisors's BCYC Position: Q3 2024 in Review

HHLR Advisors sold out of Bicycle Therapeutics (BCYC) in Q3 2024, closing a stake of 125,283 shares — an estimated $2.54M sold.

HHLR Advisors first reported a position in BCYC in Q2 2024 and held it in 1 quarter. The position peaked at $2.54M in Q2 2024. 105 funds tracked by Wall St. Rank hold BCYC as of Q3 2024.

  • HHLR Advisors reported no remaining Bicycle Therapeutics position as of Q3 2024 after selling out during the quarter.
  • HHLR Advisors sold 125,283 Bicycle Therapeutics shares in Q3 2024, an estimated $2.54M.
  • HHLR Advisors first reported a position in Bicycle Therapeutics in Q2 2024 and held it in 1 quarter.
  • HHLR Advisors's Bicycle Therapeutics position peaked at $2.54M in Q2 2024.
  • 105 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q3 2024.

Based on HHLR Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.